Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kinnate Biopharma Inc (KNTE)

Kinnate Biopharma Inc (KNTE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 125,146
  • Shares Outstanding, K 47,225
  • Annual Sales, $ 0 K
  • Annual Income, $ -116,270 K
  • 60-Month Beta 1.38
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.78
Trade KNTE with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.78
  • Most Recent Earnings $-0.65 on 11/09/23
  • Latest Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.36
  • Number of Estimates 4
  • High Estimate -0.29
  • Low Estimate -0.43
  • Prior Year -0.73
  • Growth Rate Est. (year over year) +50.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.52 +5.16%
on 03/14/24
2.69 -1.49%
on 03/28/24
+0.06 (+2.32%)
since 03/01/24
3-Month
2.20 +20.45%
on 02/09/24
2.69 -1.49%
on 03/28/24
+0.16 (+6.43%)
since 01/02/24
52-Week
1.04 +154.81%
on 10/26/23
7.18 -63.12%
on 04/14/23
-3.60 (-57.60%)
since 03/31/23

Most Recent Stories

More News
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program...

KNTE : 2.65 (-0.38%)
S&P Futures Plunge Ahead of FOMC Meeting, Oil’s Climb Raises Inflation Concerns

December S&P 500 futures (ESZ23) are trending down -0.51% this morning as market participants geared up for a big week for central banks, with the spotlight on the Federal Reserve’s interest rate decision...

ESZ23 : 4,694.27s (-0.58%)
AAPL : 166.90 (-0.65%)
AYX : 48.26 (+0.02%)
TSLA : 149.69 (-3.71%)
ARM : 105.32 (-2.08%)
KGF.LN : 248.200 (+1.97%)
NIO : 4.01 (+2.56%)
DELL : 118.67 (-0.79%)
AVGR : 3.83 (+4.22%)
KNTE : 2.65 (-0.38%)
GMED : 51.29 (+0.18%)
PLNT : 58.88 (-0.79%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END

KTTA : 7.15 (unch)
DAWN : 15.75 (+6.06%)
SWTX : 44.02 (-0.20%)
VSTM : 10.68 (-1.48%)
KNTE : 2.65 (-0.38%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

/PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue....

KTTA : 7.15 (unch)
SWTX : 44.02 (-0.20%)
DAWN : 15.75 (+6.06%)
VSTM : 10.68 (-1.48%)
KNTE : 2.65 (-0.38%)
Why Earnings Season Could Be Great for Kinnate Biopharma (KNTE)

Kinnate Biopharma (KNTE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

KNTE : 2.65 (-0.38%)
Can Kinnate Biopharma Inc. (KNTE) Climb 305% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Kinnate Biopharma Inc. (KNTE) points to a 305% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among...

KNTE : 2.65 (-0.38%)
Kinnate Biopharma Inc. (KNTE) Upgraded to Buy: Here's What You Should Know

Kinnate Biopharma Inc. (KNTE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

KNTE : 2.65 (-0.38%)
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences

SAN FRANCISCO and SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology...

KNTE : 2.65 (-0.38%)
Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022

Preclinical data from a study of the Company’s pan-RAF product candidate, KIN-2787, in combination with MEK inhibitor, also accepted for publication in the...

KNTE : 2.65 (-0.38%)
Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248

SAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on...

KNTE : 2.65 (-0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Kinnate Biopharma Inc. is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate Biopharma Inc. is based in SAN FRANCISCO, California.

See More

Key Turning Points

3rd Resistance Point 2.70
2nd Resistance Point 2.69
1st Resistance Point 2.67
Last Price 2.65
1st Support Level 2.64
2nd Support Level 2.62
3rd Support Level 2.60

See More

52-Week High 7.18
Fibonacci 61.8% 4.84
Fibonacci 50% 4.11
Fibonacci 38.2% 3.39
Last Price 2.65
52-Week Low 1.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar